Please ensure Javascript is enabled for purposes of website accessibility

Can Amgen's Earnings Keep Its Stock Soaring?

By Dan Caplinger - Apr 20, 2013 at 3:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The premier biotech has been hitting all-time record highs.

On Tuesday, Amgen (AMGN 1.11%) will release its latest quarterly results. The key to making smart investment decisions on stocks reporting earnings is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you'll be less likely to make an uninformed knee-jerk reaction to news that turns out to be exactly the wrong move.

Amgen has a strong reputation as a giant in the biotech field, having been a pioneer in the industry. Yet the company hasn't stopped striving for further growth as it pushes its efforts into promising new corners of the biologics market. Let's take an early look at what's been happening with Amgen over the past quarter and what we're likely to see in its quarterly report.

Stats on Amgen

Analyst EPS Estimate

$1.84

Change From Year-Ago EPS

14.3%

Revenue Estimate

$4.37 billion

Change From Year-Ago Revenue

8%

Earnings Beats in Past 4 Quarters

4

Source: Yahoo! Finance.

Can Amgen keep impressing Wall Street this quarter?
In recent months, analysts have only gotten more enthusiastic about Amgen's earnings prospects. They've raised their estimates for the just-ended quarter by $0.14 per share, with even more substantial boosts for both full-year 2013 and 2014 expectations. Investors have jumped on the bandwagon, sending shares soaring by more than 30% since mid-January.

Amgen has a huge presence in the biotech industry. Its Neulasta/Neupogen treatment for patients undergoing chemotherapy brings in the most revenue of any drug it sells, with $1.3 billion in worldwide sales just in the fourth-quarter of 2012 alone. Yet that dependence has raised patent-cliff concerns, as Neupogen will lose its exclusivity at the end of this year. Teva Pharmaceutical (TEVA 1.93%) has already made an agreement with Amgen to sell a biosimilar version of Neupogen beginning in November, and future efforts from other companies will inevitably bring sales down sharply next year and beyond.

To replace that lost revenue, Amgen has plenty of new prospects in the fire, with a particularly large stable of biologics in late-stage phase 3 trials. Rival Celgene (CELG) arguably has a slightly better pipeline in that more of its trial results come in during 2013, but Amgen expects to get several sets of results this year and next, which could lead to an even larger stable of products for the company.

What's unclear, though, is whether Amgen will be able to sustain its impressive revenue growth. Amgen's profit margins have fallen dramatically in recent years, and as health-care reform laws take full effect, the company could continue to see more bottom-line pressure in the years to come.

In Amgen's earnings report, watch for the company to discuss the impact that a recent German regulatory review of drug prices could have on Amgen over the long term. Germany's cost-benefit assessment framework could eventually become a model for U.S. health-care cost management as well, and as a result, it's important for Amgen to tread carefully in demonstrating its products' medical benefits and cost-effectiveness.

Click here to add Amgen to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$247.50 (1.11%) $2.73
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$8.47 (1.93%) $0.16
Celgene Corporation Stock Quote
Celgene Corporation
CELG

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.